Loading…
Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-α2a for liver cancer therapy
We report an injectable hydrogel system that incorporates interferon-α2a (IFN-α2a) for liver cancer therapy. IFN-α2a was incorporated in hydrogels composed of hyaluronic acid-tyramine (HA-Tyr) conjugates through the oxidative coupling of Tyr moieties with hydrogen peroxide (H2O2) and horseradish per...
Saved in:
Published in: | Journal of controlled release 2013-03, Vol.166 (3), p.203-210 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c370t-157c5a0565836600d195bbf7be509a37622483497711040ca9385d279a6027c13 |
---|---|
cites | cdi_FETCH-LOGICAL-c370t-157c5a0565836600d195bbf7be509a37622483497711040ca9385d279a6027c13 |
container_end_page | 210 |
container_issue | 3 |
container_start_page | 203 |
container_title | Journal of controlled release |
container_volume | 166 |
creator | Xu, Keming Lee, Fan Gao, Shu Jun Chung, Joo Eun Yano, Hirohisa Kurisawa, Motoichi |
description | We report an injectable hydrogel system that incorporates interferon-α2a (IFN-α2a) for liver cancer therapy. IFN-α2a was incorporated in hydrogels composed of hyaluronic acid-tyramine (HA-Tyr) conjugates through the oxidative coupling of Tyr moieties with hydrogen peroxide (H2O2) and horseradish peroxidase (HRP). IFN-α2a-incorporated HA-Tyr hydrogels of varying stiffness were formed by changing the H2O2 concentration. The incorporation of IFN-α2a did not affect the rheological properties of the hydrogels. The activity of IFN-α2a was furthermore well-maintained in the hydrogels with lower stiffness. Through the caspase-3/7 pathway in vitro, IFN-α2a released from HA-Tyr hydrogels inhibited the proliferation of liver cancer cells and induced apoptosis. In the study of the pharmacokinetics, a higher concentration of IFN-α2a was shown in the plasma of mice treated with IFN-α2a-incorporated hydrogels after 4h post injection, with a much higher amount of IFN-α2a delivered at the tumor tissue comparing to that of injecting an IFN-α2a solution. The tumor regression study revealed that IFN-α2a-incorporated HA-Tyr hydrogels effectively inhibited tumor growth, while the injection of an IFN-α2a solution did not demonstrate antitumor efficacy. Histological studies confirmed that tumor tissues in mice treated with IFN-α2a-incorporated HA-Tyr hydrogels showed lower cell density, with more apoptotic and less proliferating cells compared with tissues treated with an IFN-α2a solution. In addition, the IFN-α2a-incorporated hydrogel treatment greatly inhibited the angiogenesis of tumor tissues.
[Display omitted] |
doi_str_mv | 10.1016/j.jconrel.2013.01.008 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1315633331</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365913000254</els_id><sourcerecordid>1315633331</sourcerecordid><originalsourceid>FETCH-LOGICAL-c370t-157c5a0565836600d195bbf7be509a37622483497711040ca9385d279a6027c13</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhi1URJfCI0Bz7CVhbMdxfKqqqkClShygZ8txJltH2Xg7zlbax-JFeCa82i1XfBlZ8_1j6xvGPnGoOPDmy1iNPs6EUyWAywp4BdC-YSvealnWxqgztspcW8pGmXP2PqURAJSs9Tt2LqQULRdqxfr7eUS_uG7C4mnvph3FOfjC-dCXy57cJsyHRk9xjVMqwuwjbSO5JczrfFuQBsyR8s9v4YohUjGFF6TCu9nnsjwhue3-A3s7uCnhx1O9YI9f737dfi8ffny7v715KL3UsJRcaa8cqEa1smkAem5U1w26QwXGSd0IUbeyNlpzDjV4Z2SreqGNa0Boz-UFuzrO3VJ83mFa7CYkj9PkZoy7ZLnkqpH5HFB1RD3FlAgHu6WwcbS3HOxBsB3tSbA9CLbAbRacc59PT-y6Dfb_Uq9GM3B5BAYXrVtTSPbxZ56gALjWUJtMXB-JLBRfApJNPmD21QfKq7B9DP_5xF-qgZi8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1315633331</pqid></control><display><type>article</type><title>Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-α2a for liver cancer therapy</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Xu, Keming ; Lee, Fan ; Gao, Shu Jun ; Chung, Joo Eun ; Yano, Hirohisa ; Kurisawa, Motoichi</creator><creatorcontrib>Xu, Keming ; Lee, Fan ; Gao, Shu Jun ; Chung, Joo Eun ; Yano, Hirohisa ; Kurisawa, Motoichi</creatorcontrib><description>We report an injectable hydrogel system that incorporates interferon-α2a (IFN-α2a) for liver cancer therapy. IFN-α2a was incorporated in hydrogels composed of hyaluronic acid-tyramine (HA-Tyr) conjugates through the oxidative coupling of Tyr moieties with hydrogen peroxide (H2O2) and horseradish peroxidase (HRP). IFN-α2a-incorporated HA-Tyr hydrogels of varying stiffness were formed by changing the H2O2 concentration. The incorporation of IFN-α2a did not affect the rheological properties of the hydrogels. The activity of IFN-α2a was furthermore well-maintained in the hydrogels with lower stiffness. Through the caspase-3/7 pathway in vitro, IFN-α2a released from HA-Tyr hydrogels inhibited the proliferation of liver cancer cells and induced apoptosis. In the study of the pharmacokinetics, a higher concentration of IFN-α2a was shown in the plasma of mice treated with IFN-α2a-incorporated hydrogels after 4h post injection, with a much higher amount of IFN-α2a delivered at the tumor tissue comparing to that of injecting an IFN-α2a solution. The tumor regression study revealed that IFN-α2a-incorporated HA-Tyr hydrogels effectively inhibited tumor growth, while the injection of an IFN-α2a solution did not demonstrate antitumor efficacy. Histological studies confirmed that tumor tissues in mice treated with IFN-α2a-incorporated HA-Tyr hydrogels showed lower cell density, with more apoptotic and less proliferating cells compared with tissues treated with an IFN-α2a solution. In addition, the IFN-α2a-incorporated hydrogel treatment greatly inhibited the angiogenesis of tumor tissues.
[Display omitted]</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2013.01.008</identifier><identifier>PMID: 23328125</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>angiogenesis ; Animals ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - pharmacokinetics ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; apoptosis ; Apoptosis - drug effects ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Drug Carriers - chemical synthesis ; Drug Carriers - chemistry ; Female ; Humans ; Hyaluronic acid ; Hyaluronic Acid - chemistry ; hydrocolloids ; Hydrogel ; Hydrogels - chemistry ; hydrogen peroxide ; Injectable ; Injections, Subcutaneous ; Interferon ; Interferon-alpha - administration & dosage ; Interferon-alpha - pharmacokinetics ; Interferon-alpha - pharmacology ; Interferon-alpha - therapeutic use ; liver neoplasms ; Liver Neoplasms - drug therapy ; Liver Neoplasms - pathology ; Mice ; Mice, Inbred BALB C ; neoplasm cells ; peroxidase ; pharmacokinetics ; Protein delivery ; Recombinant Proteins - administration & dosage ; Recombinant Proteins - pharmacokinetics ; Recombinant Proteins - pharmacology ; Recombinant Proteins - therapeutic use ; remission ; rheological properties ; Solubility ; therapeutics ; tissues ; Tyramine - chemistry ; Xenograft Model Antitumor Assays</subject><ispartof>Journal of controlled release, 2013-03, Vol.166 (3), p.203-210</ispartof><rights>2013 Elsevier B.V.</rights><rights>Copyright © 2013 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c370t-157c5a0565836600d195bbf7be509a37622483497711040ca9385d279a6027c13</citedby><cites>FETCH-LOGICAL-c370t-157c5a0565836600d195bbf7be509a37622483497711040ca9385d279a6027c13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23328125$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Keming</creatorcontrib><creatorcontrib>Lee, Fan</creatorcontrib><creatorcontrib>Gao, Shu Jun</creatorcontrib><creatorcontrib>Chung, Joo Eun</creatorcontrib><creatorcontrib>Yano, Hirohisa</creatorcontrib><creatorcontrib>Kurisawa, Motoichi</creatorcontrib><title>Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-α2a for liver cancer therapy</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>We report an injectable hydrogel system that incorporates interferon-α2a (IFN-α2a) for liver cancer therapy. IFN-α2a was incorporated in hydrogels composed of hyaluronic acid-tyramine (HA-Tyr) conjugates through the oxidative coupling of Tyr moieties with hydrogen peroxide (H2O2) and horseradish peroxidase (HRP). IFN-α2a-incorporated HA-Tyr hydrogels of varying stiffness were formed by changing the H2O2 concentration. The incorporation of IFN-α2a did not affect the rheological properties of the hydrogels. The activity of IFN-α2a was furthermore well-maintained in the hydrogels with lower stiffness. Through the caspase-3/7 pathway in vitro, IFN-α2a released from HA-Tyr hydrogels inhibited the proliferation of liver cancer cells and induced apoptosis. In the study of the pharmacokinetics, a higher concentration of IFN-α2a was shown in the plasma of mice treated with IFN-α2a-incorporated hydrogels after 4h post injection, with a much higher amount of IFN-α2a delivered at the tumor tissue comparing to that of injecting an IFN-α2a solution. The tumor regression study revealed that IFN-α2a-incorporated HA-Tyr hydrogels effectively inhibited tumor growth, while the injection of an IFN-α2a solution did not demonstrate antitumor efficacy. Histological studies confirmed that tumor tissues in mice treated with IFN-α2a-incorporated HA-Tyr hydrogels showed lower cell density, with more apoptotic and less proliferating cells compared with tissues treated with an IFN-α2a solution. In addition, the IFN-α2a-incorporated hydrogel treatment greatly inhibited the angiogenesis of tumor tissues.
[Display omitted]</description><subject>angiogenesis</subject><subject>Animals</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - pharmacokinetics</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Drug Carriers - chemical synthesis</subject><subject>Drug Carriers - chemistry</subject><subject>Female</subject><subject>Humans</subject><subject>Hyaluronic acid</subject><subject>Hyaluronic Acid - chemistry</subject><subject>hydrocolloids</subject><subject>Hydrogel</subject><subject>Hydrogels - chemistry</subject><subject>hydrogen peroxide</subject><subject>Injectable</subject><subject>Injections, Subcutaneous</subject><subject>Interferon</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Interferon-alpha - pharmacokinetics</subject><subject>Interferon-alpha - pharmacology</subject><subject>Interferon-alpha - therapeutic use</subject><subject>liver neoplasms</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - pathology</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>neoplasm cells</subject><subject>peroxidase</subject><subject>pharmacokinetics</subject><subject>Protein delivery</subject><subject>Recombinant Proteins - administration & dosage</subject><subject>Recombinant Proteins - pharmacokinetics</subject><subject>Recombinant Proteins - pharmacology</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>remission</subject><subject>rheological properties</subject><subject>Solubility</subject><subject>therapeutics</subject><subject>tissues</subject><subject>Tyramine - chemistry</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqFkcFu1DAQhi1URJfCI0Bz7CVhbMdxfKqqqkClShygZ8txJltH2Xg7zlbax-JFeCa82i1XfBlZ8_1j6xvGPnGoOPDmy1iNPs6EUyWAywp4BdC-YSvealnWxqgztspcW8pGmXP2PqURAJSs9Tt2LqQULRdqxfr7eUS_uG7C4mnvph3FOfjC-dCXy57cJsyHRk9xjVMqwuwjbSO5JczrfFuQBsyR8s9v4YohUjGFF6TCu9nnsjwhue3-A3s7uCnhx1O9YI9f737dfi8ffny7v715KL3UsJRcaa8cqEa1smkAem5U1w26QwXGSd0IUbeyNlpzDjV4Z2SreqGNa0Boz-UFuzrO3VJ83mFa7CYkj9PkZoy7ZLnkqpH5HFB1RD3FlAgHu6WwcbS3HOxBsB3tSbA9CLbAbRacc59PT-y6Dfb_Uq9GM3B5BAYXrVtTSPbxZ56gALjWUJtMXB-JLBRfApJNPmD21QfKq7B9DP_5xF-qgZi8</recordid><startdate>20130328</startdate><enddate>20130328</enddate><creator>Xu, Keming</creator><creator>Lee, Fan</creator><creator>Gao, Shu Jun</creator><creator>Chung, Joo Eun</creator><creator>Yano, Hirohisa</creator><creator>Kurisawa, Motoichi</creator><general>Elsevier B.V</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130328</creationdate><title>Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-α2a for liver cancer therapy</title><author>Xu, Keming ; Lee, Fan ; Gao, Shu Jun ; Chung, Joo Eun ; Yano, Hirohisa ; Kurisawa, Motoichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c370t-157c5a0565836600d195bbf7be509a37622483497711040ca9385d279a6027c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>angiogenesis</topic><topic>Animals</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - pharmacokinetics</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Drug Carriers - chemical synthesis</topic><topic>Drug Carriers - chemistry</topic><topic>Female</topic><topic>Humans</topic><topic>Hyaluronic acid</topic><topic>Hyaluronic Acid - chemistry</topic><topic>hydrocolloids</topic><topic>Hydrogel</topic><topic>Hydrogels - chemistry</topic><topic>hydrogen peroxide</topic><topic>Injectable</topic><topic>Injections, Subcutaneous</topic><topic>Interferon</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Interferon-alpha - pharmacokinetics</topic><topic>Interferon-alpha - pharmacology</topic><topic>Interferon-alpha - therapeutic use</topic><topic>liver neoplasms</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - pathology</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>neoplasm cells</topic><topic>peroxidase</topic><topic>pharmacokinetics</topic><topic>Protein delivery</topic><topic>Recombinant Proteins - administration & dosage</topic><topic>Recombinant Proteins - pharmacokinetics</topic><topic>Recombinant Proteins - pharmacology</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>remission</topic><topic>rheological properties</topic><topic>Solubility</topic><topic>therapeutics</topic><topic>tissues</topic><topic>Tyramine - chemistry</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Keming</creatorcontrib><creatorcontrib>Lee, Fan</creatorcontrib><creatorcontrib>Gao, Shu Jun</creatorcontrib><creatorcontrib>Chung, Joo Eun</creatorcontrib><creatorcontrib>Yano, Hirohisa</creatorcontrib><creatorcontrib>Kurisawa, Motoichi</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Keming</au><au>Lee, Fan</au><au>Gao, Shu Jun</au><au>Chung, Joo Eun</au><au>Yano, Hirohisa</au><au>Kurisawa, Motoichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-α2a for liver cancer therapy</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2013-03-28</date><risdate>2013</risdate><volume>166</volume><issue>3</issue><spage>203</spage><epage>210</epage><pages>203-210</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>We report an injectable hydrogel system that incorporates interferon-α2a (IFN-α2a) for liver cancer therapy. IFN-α2a was incorporated in hydrogels composed of hyaluronic acid-tyramine (HA-Tyr) conjugates through the oxidative coupling of Tyr moieties with hydrogen peroxide (H2O2) and horseradish peroxidase (HRP). IFN-α2a-incorporated HA-Tyr hydrogels of varying stiffness were formed by changing the H2O2 concentration. The incorporation of IFN-α2a did not affect the rheological properties of the hydrogels. The activity of IFN-α2a was furthermore well-maintained in the hydrogels with lower stiffness. Through the caspase-3/7 pathway in vitro, IFN-α2a released from HA-Tyr hydrogels inhibited the proliferation of liver cancer cells and induced apoptosis. In the study of the pharmacokinetics, a higher concentration of IFN-α2a was shown in the plasma of mice treated with IFN-α2a-incorporated hydrogels after 4h post injection, with a much higher amount of IFN-α2a delivered at the tumor tissue comparing to that of injecting an IFN-α2a solution. The tumor regression study revealed that IFN-α2a-incorporated HA-Tyr hydrogels effectively inhibited tumor growth, while the injection of an IFN-α2a solution did not demonstrate antitumor efficacy. Histological studies confirmed that tumor tissues in mice treated with IFN-α2a-incorporated HA-Tyr hydrogels showed lower cell density, with more apoptotic and less proliferating cells compared with tissues treated with an IFN-α2a solution. In addition, the IFN-α2a-incorporated hydrogel treatment greatly inhibited the angiogenesis of tumor tissues.
[Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>23328125</pmid><doi>10.1016/j.jconrel.2013.01.008</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0168-3659 |
ispartof | Journal of controlled release, 2013-03, Vol.166 (3), p.203-210 |
issn | 0168-3659 1873-4995 |
language | eng |
recordid | cdi_proquest_miscellaneous_1315633331 |
source | ScienceDirect Freedom Collection 2022-2024 |
subjects | angiogenesis Animals Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use apoptosis Apoptosis - drug effects Cell Line, Tumor Cell Proliferation - drug effects Drug Carriers - chemical synthesis Drug Carriers - chemistry Female Humans Hyaluronic acid Hyaluronic Acid - chemistry hydrocolloids Hydrogel Hydrogels - chemistry hydrogen peroxide Injectable Injections, Subcutaneous Interferon Interferon-alpha - administration & dosage Interferon-alpha - pharmacokinetics Interferon-alpha - pharmacology Interferon-alpha - therapeutic use liver neoplasms Liver Neoplasms - drug therapy Liver Neoplasms - pathology Mice Mice, Inbred BALB C neoplasm cells peroxidase pharmacokinetics Protein delivery Recombinant Proteins - administration & dosage Recombinant Proteins - pharmacokinetics Recombinant Proteins - pharmacology Recombinant Proteins - therapeutic use remission rheological properties Solubility therapeutics tissues Tyramine - chemistry Xenograft Model Antitumor Assays |
title | Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-α2a for liver cancer therapy |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T09%3A43%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Injectable%20hyaluronic%20acid-tyramine%20hydrogels%20incorporating%20interferon-%CE%B12a%20for%20liver%20cancer%20therapy&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Xu,%20Keming&rft.date=2013-03-28&rft.volume=166&rft.issue=3&rft.spage=203&rft.epage=210&rft.pages=203-210&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2013.01.008&rft_dat=%3Cproquest_cross%3E1315633331%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c370t-157c5a0565836600d195bbf7be509a37622483497711040ca9385d279a6027c13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1315633331&rft_id=info:pmid/23328125&rfr_iscdi=true |